Your browser doesn't support javascript.
loading
Brain 18FDG-PET pattern in patients with alcohol-related cognitive impairment.
Clergue-Duval, Virgile; Questel, Frank; Azuar, Julien; Paquet, Claire; Cognat, Emmanuel; Amami, Jihed; Queneau, Mathieu; Dereux, Alexandra; Barré, Thomas; Bellivier, Frank; Farid, Karim; Vorspan, Florence.
Afiliação
  • Clergue-Duval V; Département de Psychiatrie et de Médecine Addictologique, Groupe Hospitalier Saint-Louis Lariboisière Fernand-Widal, Hôpital Fernand Widal, Paris, France. virgile.clergue-duval@aphp.fr.
  • Questel F; Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université de Paris, Paris, France. virgile.clergue-duval@aphp.fr.
  • Azuar J; Faculté de Médecine, Université de Paris, 75475, Paris Cedex 10, France. virgile.clergue-duval@aphp.fr.
  • Paquet C; Département de Psychiatrie et de Médecine Addictologique, Groupe Hospitalier Saint-Louis Lariboisière Fernand-Widal, Hôpital Fernand Widal, Paris, France.
  • Cognat E; Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université de Paris, Paris, France.
  • Amami J; Département de Psychiatrie et de Médecine Addictologique, Groupe Hospitalier Saint-Louis Lariboisière Fernand-Widal, Hôpital Fernand Widal, Paris, France.
  • Queneau M; Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université de Paris, Paris, France.
  • Dereux A; Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université de Paris, Paris, France.
  • Barré T; APHP, Centre de Neurologie Cognitive, Groupe Hospitalier Saint-Louis Lariboisière Fernand-Widal, Paris, France.
  • Bellivier F; Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université de Paris, Paris, France.
  • Farid K; APHP, Centre de Neurologie Cognitive, Groupe Hospitalier Saint-Louis Lariboisière Fernand-Widal, Paris, France.
  • Vorspan F; Département de Psychiatrie et de Médecine Addictologique, Groupe Hospitalier Saint-Louis Lariboisière Fernand-Widal, Hôpital Fernand Widal, Paris, France.
Eur J Nucl Med Mol Imaging ; 47(2): 281-291, 2020 02.
Article em En | MEDLINE | ID: mdl-31428832
ABSTRACT

PURPOSE:

Brain positron emission tomography using 18F-fluorodeoxyglucose (18FDG-PET) provides a metabolic assessment of brain function that is useful for differential diagnosis among several neurodegenerative diseases manifested by cognitive impairment (CI). The purpose of the study is to describe the pattern of 18FDG-PET abnormalities in patients with CI related to alcohol use disorder.

METHODS:

Patients admitted to the addiction medicine department of a university hospital in Paris between January 2017 and October 2018 with a confirmed diagnosis of alcohol-related cognitive impairment (ARCI) or Wernicke encephalopathy (WE) were included. Brain 18FDG-PET uptake was measured after at least 1 month of monitored abstinence from alcohol. Standardized uptake values were obtained for 13 regions of interest (ROI) and normalized to the pons. Individual patients' ROI Z-scores were calculated from healthy sex- and age-matched controls provided by Cortex ID software.

RESULTS:

Twenty-five patients were included in the analysis (20 males and 5 females; mean age 57.6 years (45-76 years old)). The group consisted of 19 ARCI and 6 WE cases. The mean hypometabolism was most severe in the prefrontal medial cortex (PFM) (- 2.80 (± 1.30)), the prefrontal lateral cortex (- 2.20 (± 1.35)), and the anterior cingulate cortex (- 2.24 (± 1.19)). Hypometabolism (Z-score < - 2) was most frequent in the PFM (72.0% of the sample, N = 18). Other regions were also affected (with 5.32/13 hypometabolic ROIs on average (SD = 4.16, range 0-13)). The Z-scores in the 13 ROIs did not differ significantly between the ARCI and WE patients (p ≥ 0.05).

CONCLUSIONS:

Predominant prefrontal and cingulate cortex hypometabolism was the most frequent brain 18FDG-PET pattern in our sample of patients with ARCI and WE.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fluordesoxiglucose F18 / Disfunção Cognitiva Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Nucl Med Mol Imaging Assunto da revista: MEDICINA NUCLEAR Ano de publicação: 2020 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fluordesoxiglucose F18 / Disfunção Cognitiva Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Nucl Med Mol Imaging Assunto da revista: MEDICINA NUCLEAR Ano de publicação: 2020 Tipo de documento: Article País de afiliação: França